Form 4 for MPLT MapLight Therapeutics, Inc.
Accepted 2025-10-28 00:00:00 ET · period of report 2025-10-27 · accession 0001658918-25-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-28 | 2025-10-28 | MPLT | Kroeger Christopher A. | CEO, Dir | C - Cnv Deriv | — | +3,895 | 229.6K | +2% | — |
| D | 2025-10-28 | 2025-10-27 | MPLT | Kroeger Christopher A. | CEO, Dir | A - Grant | $0.00 | +225.7K | 225.7K | New | $0 |
| D | 2025-10-28 | 2025-10-28 | MPLT | Kroeger Christopher A. | CEO, Dir | C - Cnv Deriv | $0.00 | -65.5K | 0 | -100% | $0 |
| D | 2025-10-28 | 2025-10-27 | MPLT | Kroeger Christopher A. | CEO, Dir | A - Grant | $0.00 | +916.2K | 916.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Voting Common Stock | 2025-10-28 | C | A | 3,895 | — | 229,588 | D | — | — | (F3) The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's IPO for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. |
| 2 | Common | Voting Common Stock | 2025-10-27 | A | A | 225,693 | $0.00 | 225,693 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on October 1, 2026, and 1/16th of the RSUs shall vest on each subsequent January 1, April 1, July 1 and October 1 thereafter, subject to the Reporting Person's continued service through each vesting date. (F2) Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. |
| 3 | Derivative | Series C Preferred Stock | 2025-10-28 | C | D | 65,477 | $0.00 | 0 | D | — · — to — | 3,895 Voting Common Stock | (F3) The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's IPO for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. |
| 4 | Derivative | Employee Stock Option (right to buy) | 2025-10-27 | A | A | 916,164 | $0.00 | 916,164 | D | $17.00 · — to 2035-10-26 | 916,164 Voting Common Stock | (F5) 1/4th of the total shares underlying the option shall vest on October 1, 2026, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date. |